At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before.
Syndax is currently focused on developing an innovative pipeline of combination therapies in multiple cancer indications.
Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive breast cancer, and as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.
Concurrently, Syndax is also developing SNDX-6352 (also known as UCB6352), an IND-ready anti-CSF-1R monoclonal antibody, to potentially enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. We expect to advance SNDX-6352 into the clinic later this year.
Syndax is headquartered in Waltham, Massachusetts.